DRW Securities’s Avadel Pharmaceuticals AVDL Stock Holding History

DRW Securities’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$107K	–	312
2022 Q4	$107K	Buy	+15,000	New	+$105K	﹤0.01%	245

Other funds holding AVDL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

DRW Securities's AVDL Position: Q1 2023 in Review

DRW Securities sold out of Avadel Pharmaceuticals (AVDL) in Q1 2023, closing a stake of 15,000 shares — an estimated $107K sold.

DRW Securities first reported a position in AVDL in Q4 2022 and held it in 1 quarter. The position peaked at $107K in Q4 2022. 93 funds tracked by Wall St. Rank hold AVDL as of Q1 2023.

DRW Securities reported no remaining Avadel Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
DRW Securities sold 15,000 Avadel Pharmaceuticals shares in Q1 2023, an estimated $107K.
DRW Securities first reported a position in Avadel Pharmaceuticals in Q4 2022 and held it in 1 quarter.
DRW Securities's Avadel Pharmaceuticals position peaked at $107K in Q4 2022.
93 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2023.

Based on DRW Securities's 13F filing for Q1 2023, filed 15 May 2023.